A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression

Trial Profile

A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Fibromyalgia; Musculoskeletal pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 May 2014 Results presented at the 33rd Annual Scientific Meeting of the American Pain Society.
    • 03 May 2014 Results according to baseline antidepressant class presented at the 33rd Annual Scientific Meeting of the American Pain Society.
    • 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top